Paul Geyer
Angel Investor
Vancouver, Canada
Paul Geyer is a seed investor in Vancouver focused on Health Care and Fitness. Paul Geyer, a successful Medtech Entrepreneur and experienced Board member. Over the past 20 years Paul founded and led two companies through their growth phase, in one case to a successful private exit and in the other case through growth as a public company with numerous acquisitions. Both companies have grown to be anchor medical devicecompanies in the Vancouver area, employing more than 350 people.In 1991 he founded Mitroflow International Inc., a tissue heart valve company. Paul grew the company from 9 employees to more than 125 employees in 1999. In 1999 Paul sold Mitroflow to Sulzer Medica, for more than $50 mil. Paul's leadership resulted in Mitroflow growing to more than 200 employees, making it one of the largest medical devices companies in the Vancouver area. In 2001 Paul started Medical Ventures, a new specialty vascular device company where he is currently Chairman of the Board. From its inception to June 2008, Geyer held the position of CEO at Medical Ventures (now Neovasc) and was responsible for raising over $40 million in Equity financing and growing the company’s product portfolio through internal development and the acquisition of 3 other companies. In 2008 Paul began focusing on sharing is expertise to assist other Entrepreneurs to build successful businesses, through his involvement as a mentor or Board member. He also focused on building the local community through his involvement as a Board member of BC technology industry association, along with a number of non-profit community based organizations. Paul is actively engaged as a Philanthropist, as Chairman of the Board of Social Venture Partners Vancouver, involved with Science World, Entrepreneurship at UBC, Project Somos Children’s Village and other organizations.Paul is currently the CEO of LightIntegra Technology Inc., a spin-off from Canadian Blood Services which has developed the ThromboLux technology, used to determine platelet quality for blood transfusions.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Paul Geyer invests in
Stages Paul Geyer invests in
Countries Paul Geyer invests in
Round sizes
Round size
- Seed
- $1.1M–$6M
Investment Focus
Industry
- Health Care 6 (75%)
- Fitness 2 (25%)
- Wellness 2 (25%)
- Medical Device 2 (25%)
- Mobile 1 (13%)
Stage
- Seed 4 (50%)
- Series A 2 (25%)
- Funding Round 1 (13%)
- Convertible Note 1 (13%)
Country
- Canada 6 (75%)
- United States 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
VitaminLab
|
VitaminLab takes your health history, our nutrient testing or health data, and uses our matching algorithm to create an all-in-one personalized supplement that impacts your health. The company, run by a team of pharmacists and health care professionals, was founded to change the status quo of the supplement industry. | Series A / May 08, 2023 | |
Sonic Incytes
|
Sonic Incytes is a medical device start-up company developing quantitative ultrasound for point-of-care diagnostic and procedure guidance. our mission to enable routine assessment and management of liver health, with diagnostic accuracy you can count on. | $7.3M / Series A / Dec 07, 2021 | |
Stoko design
|
Stoko was born in 2017 when an Olympian and an engineer set out to build a knee brace that athletes actually wanted to wear. Our team went back to basics, designing a completely new experience. By incorporating support directly into apparel, we are able to offer a product that is just as supportive as a rigid brace, but fits seamlessly into yourlife. | $6M / Seed / May 10, 2021 | |
Arbutus Medical
|
Every hospital in the world is faced with a major challenge - the rising cost of heathcare - we want to do something about it. Arbutus Medical’s purpose is to develop a portfolio of “frugal innovation” devices that save costs for hospitals and improve access to orthopedic surgery for 5 million patients by 2030. Arbutus Medical's flagshipproduct is a radically affordable orthopaedic power tool system that is used in North American Trauma Centers, veterinary hospitals, military deployments, NGO missions, and hospitals in over 30 low- and middle-income countries worldwide. | $1.2M / Seed / Jul 29, 2020 | |
HeadCheck Health
|
HeadCheck Health is a digital health venture providing concussion management and risk mitigation technologies to sports organizations. Concussion has become the #1 cause of negative human outcomes and financial risk for sports organizations globally. The human impact includes both known and unknown long-term deficits that affect an athlete’sability to play sport, contribute to the workforce, and have a high quality of life. The financial and legal impact for sports organizations and their employees totals billions of dollars annually, materially affecting these businesses and their ability to properly insure these risks. Neurological injury coverage is quickly disappearing from insurance policies, potentially leaving sports organizations with large under-insured risks.In an attempt to control these risks and provide peace of mind to athletes and their families, sports leagues and governing bodies have implemented widespread concussion policies. These policies provide prescriptive actions that all teams must take in advance, during, and following the identification of concussion to ensure sport remains safe for the athlete and the organization. However, the way sports leagues and governing bodies are implementing these concussion policies is proven to be ineffective, leaving sports organizations globally even more exposed to mismanagement risks.HeadCheck Health has a solution that will provide a win for athletes and sports organizations globally. Our suite of digital tools simplifies the process of executing and monitoring concussion protocols. The HeadCheck system can be tailored to any level or sport’s concussion protocol, and includes all aspects of organizational best practices in complying with the relevant concussion policy and/or laws. This may include educational requirements, actual testing or documentation required to identify and report the injury, and management of the injury according to the sport’s safe return-to-play protocol. | Seed / Mar 18, 2019 | |
Blue Mesa Health
|
We have reached an inflection point in history where chronic disease is killing more people than infectious disease. Seven out of every ten deaths and 86% of the health care costs in the United States are attributable to chronic disease. There are similar statistics in other countries.Our digital therapeutics product, Transform, delivers adigital therapeutics solution specifically targeted at diabetes prevention. Digital therapeutics combines the latest advances in software, hardware, cloud infrastructure and applied behavioral psychology to deliver a platform preventive health coaching in a convenient and flexible format.In 2018, we have launched our product in Latin America and the Middle East with a vision to be the global leader in culturally diverse, technology-driven behavioral change programs. | $1.3M / Seed / Jul 24, 2017 | |
|
Arbutus Medical
|
Every hospital in the world is faced with a major challenge - the rising cost of heathcare - we want to do something about it. Arbutus Medical’s purpose is to develop a portfolio of “frugal innovation” devices that save costs for hospitals and improve access to orthopedic surgery for 5 million patients by 2030. Arbutus Medical's flagshipproduct is a radically affordable orthopaedic power tool system that is used in North American Trauma Centers, veterinary hospitals, military deployments, NGO missions, and hospitals in over 30 low- and middle-income countries worldwide. | $1.6M / Convertible Note / Mar 29, 2017 | |
WealthBar
|
WealthBar is building Canada's first online portfolio management services. This brings together technology, financial advice and expert portfolio management to make online investing simpler, easier and cheaper than the alternatives. The end result is Canada's very first completely online financial advisor service. | $5.5M / May 10, 2016 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Paul Geyer invest in?
Paul Geyer invests primarily in Health Care, Fitness and Wellness startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Paul Geyer's check size?
Paul Geyer typically joins rounds of $1.1M–$6M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Paul Geyer participates in.
When did Paul Geyer last invest?
The most recent investment recorded for Paul Geyer closed in May 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
